Thrombus - 2006

The validity of pre-test probability scoring to predict PE in routine practice
P Jayne Norcliffe and Christopher WH Davies
pp 1-5
Pre-test probability (PTP) scoring, such as the Wells score, may help estimate the likelihood of pulmonary embolism (PE) before diagnostic tests are performed and may exclude PE without the need for further investigation. The British Thoracic Society (BTS) has published a PTP scoring system – which has not yet been validated – in its guidelines for management of PE. This study assesses the validity of the BTS and Wells PTP scores in a UK population.
Comment: Training for anticoagulation management
David Fitzmaurice
pp 2-2
One of the frustrations of working within the area of thrombosis and haemostasis has been the lack of recognition of the importance of anticoagulation therapy. For example, a 68% reduction in the risk of stroke for patients with atrial fibrillation makes warfarin one of the most powerful therapeutic interventions we have. Despite this, and possibly because warfarin is not a patented drug, it is only recently that anticoagulation services have been taken seriously; for example, with their inclusion in the new Quality and Outcomes Framework for primary care.
Use of low molecular weight heparins in the long-term treatment of VTE
Marios E Daskalopoulos and Christos D Liapis
pp 6-7
Low molecular weight heparins (LMWHs) have successfully replaced unfractionated heparin (UFH) both in the prevention and in the initial treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE). Current research is focused on evaluation of the effectiveness, safety and costeffectiveness of LMWHs in the long-term treatment of venous thromboembolism (VTE) compared with conventional treatment with UFH followed by oral anticoagulants (OAs).
A problem of recurrent DVT despite adequate treatment with warfarin
Sarah Bond
pp 8-8
A 59-year-old man who is paraplegic as a result of transverse myelitis suffered his first deep vein thrombosis (DVT) in 1997 and had radiologically confirmed pulmonary embolism (PE) soon afterwards in 1998. As a result of this, he was recommended for long-term treatment with warfarin at a target international normalised ratio (INR) range of 2–3.
Inferior vena caval filters: current concepts
Hasan I Hasan and Matthew B Matson
pp 9-11
Venous thromboembolism (VTE) is a major cause of morbidity and mortality worldwide, with an estimated incidence of 100 per 100,000 population per year. Pulmonary embolism (PE) is the most dangerous complication of VTE and arises due to thrombus propagation from deep vein thrombosis (DVT), usually from the lower limbs or pelvis.

Thrombus was previously supported by Bayer from 2014 to 2016, by Boehringer Ingelheim from 2009 to 2013, by sanofi-aventis from 2007 to 2008 and by Leo Pharma from 1998 to 2006.

The data, opinions and statements appearing in the articles herein are those of the contributor(s) concerned; they are not necessarily endorsed by the sponsor, publisher, Editor or Editorial Board. Accordingly the sponsor, publisher, Editor and Editorial Board and their respective employees, officers and agents accept no liability for the consequences of any such inaccurate or misleading data, opinion or statement.

The title Thrombus is the property of Hayward Medical Publishing and PMGroup Worldwide Ltd and, together with the content, is bound by copyright. Copyright © 2019 PMGroup Worldwide Ltd. All rights reserved. The information contained on the site may not be reproduced, distributed or published, in whole or in part, in any form without the permission of the publishers. All correspondence should be addressed to:

ISSN 1369-8117 (Print)  ISSN 2045-7855 (Online)